Hepatitis crónica por virus B. Historia natural y tratamiento

Lavanchy, 2004, Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures, J Viral Hepat, 11, 97, 10.1046/j.1365-2893.2003.00487.x Pons Renedo, 2008, Farmacología del tratamiento de las infecciones por el virus C y B de la hepatitis, Interferones. Antivirales. Medicine, 10, 555 Hadziyannis, 2011, Natural history of chronic hepatitis B in Euro-Mediterranean and African countries, J Hepatol, 55, 183, 10.1016/j.jhep.2010.12.030 McMahon, 2009, The influence of hepatitis B virus genotype and subgenotype on the natural history of chronic hepatitis B, Hepatol Int, 3, 334, 10.1007/s12072-008-9112-z Lok, 2009, Chronic hepatitis B: update 2009, Hepatology, 50, 1, 10.1002/hep.23190 Lok, 2011, 615 Ganem, 2004, Hepatitis B virus infection-natural history and clinical consequences, N Engl J Med, 350, 1118, 10.1056/NEJMra031087 McMahon, 2009, The natural history of chronic hepatitis B virus infection, Hepatology, 49, S45, 10.1002/hep.22898 Chen, 2010, Carriers of inactive hepatitis B virus are still at risk for hepatocellular carcinoma and liver-related death, Gastroenterology, 138, 1747, 10.1053/j.gastro.2010.01.042 Liaw, 2011, Clinical utility of hepatitis B surface antigen quantitation in patients with chronic hepatitis B: a review, Hepatology, 53, 2121, 10.1002/hep.24364 Ahn, 2005, Long-term clinical and histological outcomes in patients with spontaneous hepatitis B surface antigen seroclearance, J Hepatol, 42, 188, 10.1016/j.jhep.2004.10.026 Simonetti, 2010, Clearance of hepatitis B surface antigen and risk of hepatocellular carcinoma in a cohort chronically infected with hepatitis B virus, Hepatology, 51, 1531, 10.1002/hep.23464 2009, EASL Clinical Practice Guidelines: management of chronic hepatitis B, J Hepatol, 50, 227, 10.1016/j.jhep.2008.10.001 Raimondo, 2008, Statements from the Taormina expert meeting on occult hepatitis B virus infection, J Hepatol, 49, 652, 10.1016/j.jhep.2008.07.014 Said, 2011, An overview of occult hepatitis B virus infection, World J Gastroenterol, 17, 1927, 10.3748/wjg.v17.i15.1927 Chotiyaputta, 2010, Endpoints of hepatitis B treatment, J Viral Hepat, 17, 675, 10.1111/j.1365-2893.2010.01369.x Papatheodoridis, 2010, Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review, J Hepatol, 53, 348, 10.1016/j.jhep.2010.02.035 Liaw, 2008, Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update, Hepatol Int, 2, 263, 10.1007/s12072-008-9080-3 Degertekin, 2009, Indications for therapy in hepatitis B, Hepatology, 49, S129, 10.1002/hep.22931 Jafri, 2010, Antiviral therapy for chronic hepatitis B, Clin Liver Dis, 14, 425, 10.1016/j.cld.2010.05.005 Alexander, 1987, Loss of HBsAg with interferon therapy in chronic hepatitis B virus infection, Lancet, 2, 66, 10.1016/S0140-6736(87)92735-8 Buster, 2009, Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa, Gastroenterology, 137, 2002, 10.1053/j.gastro.2009.08.061 Ayoub, 2011, Review article: current antiviral therapy of chronic hepatitis B, Aliment Pharmacol Ther, 34, 1145, 10.1111/j.1365-2036.2011.04869.x Hughes, 2011, Hepatitis delta virus, Lancet, 378, 73, 10.1016/S0140-6736(10)61931-9 Brunetto, 2009, Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B, Hepatology, 49, 1141, 10.1002/hep.22760 Petersen, 2011, HBV treatment and pregnancy, J Hepatol, 55, 1171, 10.1016/j.jhep.2011.06.007 Liaw, 2000, Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group, Gastroenterology, 119, 172, 10.1053/gast.2000.8559 Woo, 2010, Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: a systematic review and Bayesian meta-analyses, Gastroenterology, 139, 1218, 10.1053/j.gastro.2010.06.042 Marcellin, 2010, Continued efficacy and safety through 4 years of tenofovir disoproxil fumarate (TDF) treatment in HBeAg negative patients with chronic hepatitis B (study 102): preliminary análisis, Hepatology, 52, 555A Heathcote, 2010, Long term (4 years) efficacy and safety of tenofovir disoproxil fumarate (TDF) treatment in HBeAG-positive patients (HBeAg+) with chronic hepatitis B (Study 103): preliminary análisis, Hepatology, 52, 556A Seto, 2011, Tenofovir disoproxil fumarate for the treatment of chronic hepatitis B monoinfection, Hepatol Int, 19 Schiff, 2011, Long-term treatment with entecavir induces reversal of advanced fibrosis or cirrhosis in patients with chronic hepatitis B, Clin Gastroenterol Hepatol, 9, 274, 10.1016/j.cgh.2010.11.040 Chang, 2010, Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B, Hepatology, 52, 886, 10.1002/hep.23785 Tenney, 2009, Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy, Hepatology, 49, 1503, 10.1002/hep.22841 Chang, 2010, Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B, Hepatology, 51, 422, 10.1002/hep.23327 Reijnders, 2010, Antiviral effect of entecavir in chronic hepatitis B: influence of prior exposure to nucleos(t)ide analogues, J Hepatol, 52, 493, 10.1016/j.jhep.2010.01.012 Zoutendijk, 2011, Entecavir treatment for chronic hepatitis B: adaptation is not needed for the majority of naïve patients with a partial virological response, Hepatology, 54, 443, 10.1002/hep.24406 Lange, 2009, Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function, Hepatology, 50, 2001, 10.1002/hep.23346 Ko, 2011, Management of hepatitis B, Clin Gastroenterol Hepatol, 9, 385, 10.1016/j.cgh.2010.12.015 Hongthanakorn, 2011, Virological breakthrough and resistance in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice, Hepatology, 53, 1854, 10.1002/hep.24318 Massoumi, 2011, Management of chronic hepatitis B, Eur J Gastroenterol Hepatol, 23, 642, 10.1097/MEG.0b013e3283474add Wedemeyer, 2011, Peginterferon plus adefovir versus either drug alone for hepatitis delta, N Engl J Med, 27, 322, 10.1056/NEJMoa0912696 Tillmann, 2011, Management of severe acute to fulminant hepatitis B: to treat or not to treat or when to treat?, Liver Int, 15, 1